Details
Stereochemistry | ACHIRAL |
Molecular Formula | C21H23N3OS |
Molecular Weight | 365.492 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
OC1CCN(CCCN2C3=CC(=CC=C3SC4=C2C=CC=C4)C#N)CC1
InChI
InChIKey=LUALIOATIOESLM-UHFFFAOYSA-N
InChI=1S/C21H23N3OS/c22-15-16-6-7-21-19(14-16)24(18-4-1-2-5-20(18)26-21)11-3-10-23-12-8-17(25)9-13-23/h1-2,4-7,14,17,25H,3,8-13H2
DescriptionSources: https://www.drugbank.ca/drugs/DB01608Curator's Comment: description was created based on several sources, including
http://www.rlsnet.ru/mnn_index_id_1016.htm#primenenie--veshhestva-periciazin | https://www.ncbi.nlm.nih.gov/pubmed/7918347 | https://www.ncbi.nlm.nih.gov/pubmed/24825770
Sources: https://www.drugbank.ca/drugs/DB01608
Curator's Comment: description was created based on several sources, including
http://www.rlsnet.ru/mnn_index_id_1016.htm#primenenie--veshhestva-periciazin | https://www.ncbi.nlm.nih.gov/pubmed/7918347 | https://www.ncbi.nlm.nih.gov/pubmed/24825770
Periciazine (INN), also known as pericyazine (BAN) or Propericiazine, is a drug that belongs to the phenothiazine class of typical antipsychotics. Pericyazine is not approved for sale in the United States. It is commonly sold in Canada and Russia under the tradename Neuleptil and in the United Kingdom and Australia under the tradename Neulactil. The primary uses of pericyazine include the short-term treatment of severe anxiety or tension and in the maintenance treatment of psychotic disorders such as schizophrenia. There is insufficient evidence to determine whether periciazine is more or less effective than other antipsychotics. Pericyazine is a rather sedating and anticholinergic antipsychotic, and despite being classed with the typical antipsychotics, its risk of extrapyramidal side effects is comparatively low. It has a relatively high risk of causing hyperprolactinemia and a moderate risk of causing weight gain and orthostatic hypotension.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL217 Sources: https://books.google.ru/books?isbn=1444315161 |
|||
Target ID: CHEMBL2056 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7918347 |
10.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Neuleptil Approved UseUnknown |
|||
Primary | Neuleptil Approved UseUnknown |
|||
Primary | Neuleptil Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Use of pimozide in the Pisa syndrome. | 1992 Aug |
|
Spectrophotometric determination of cerium(IV) using a phenothiazine derivative. | 2002 Feb |
|
Dose-related effects of propericiazine in rats. | 2003 Feb |
|
Atypical properties of several classes of antipsychotic drugs on the basis of differential induction of Fos-like immunoreactivity in the rat brain. | 2004 Nov 26 |
|
Interactions between antiepileptic and antipsychotic drugs. | 2006 |
|
Relationship between obesity and antipsychotic drug use in the adult population: a longitudinal, retrospective claim database study in Primary Care settings. | 2008 Feb |
|
Mechanism of interaction between human serum albumin and N-alkyl phenothiazines studied using spectroscopic methods. | 2008 Jun 9 |
|
Symptoms and sleep patterns during inpatient treatment of methamphetamine withdrawal: a comparison of mirtazapine and modafinil with treatment as usual. | 2008 Oct |
|
Antipsychotics and risk of venous thromboembolism: A population-based case-control study. | 2009 Aug 9 |
|
Neuroleptic malignant syndrome or a statin drug reaction? A case report. | 2009 Nov-Dec |
|
All is not lost: utilizing continuous remote ILR monitoring to diagnose syncope. | 2010 Jun 1 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24825770
50 mg/day for two days, thereafter a flexible dosage schedule was followed until therapeutic effect achieved.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7918347
One hundred microlitres of [3H]SCH23390 (1 nM, 90 Ci/mmol), competing drug solution (100 mkl of variable concentrations) and 50 mM Tris-HCl buffer (700 gl) containing no NaCl or KCI were placed in glass tubes. The solutions were stirred using a vortex mixer. One hundred microlitres of membrane preparation (2.5 mg wet tissue/tube) were added and the solution was again stirred using a vortex mixer. Solutions were incubated for 30 min at 37 C. Incubations were terminated by rapid filtration under vacuum using Whatman GF/B filters (24 mm diameter). The tubes and filters were rinsed with 6 ml ice-cold saline. The filters were punched out and placed in a 20 ml glass vial with 10 ml scintillation cocktail. After the samples stood six hours, radioactivities were measured using a Beckman LS 7800 liquid scintillation counter. The specific bound was defined as the total amount of [3H]SCH23390 bound (zero unlabelled ligands) minus the nonspecific amount bound (binding in presence of 1mkM SCH23390).
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C29710
Created by
admin on Fri Dec 15 15:14:06 GMT 2023 , Edited by admin on Fri Dec 15 15:14:06 GMT 2023
|
||
|
WHO-ATC |
N05AC01
Created by
admin on Fri Dec 15 15:14:06 GMT 2023 , Edited by admin on Fri Dec 15 15:14:06 GMT 2023
|
||
|
WHO-VATC |
QN05AC01
Created by
admin on Fri Dec 15 15:14:06 GMT 2023 , Edited by admin on Fri Dec 15 15:14:06 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2622-26-6
Created by
admin on Fri Dec 15 15:14:06 GMT 2023 , Edited by admin on Fri Dec 15 15:14:06 GMT 2023
|
PRIMARY | |||
|
220-071-3
Created by
admin on Fri Dec 15 15:14:06 GMT 2023 , Edited by admin on Fri Dec 15 15:14:06 GMT 2023
|
PRIMARY | |||
|
DTXSID5045910
Created by
admin on Fri Dec 15 15:14:06 GMT 2023 , Edited by admin on Fri Dec 15 15:14:06 GMT 2023
|
PRIMARY | |||
|
8766
Created by
admin on Fri Dec 15 15:14:06 GMT 2023 , Edited by admin on Fri Dec 15 15:14:06 GMT 2023
|
PRIMARY | RxNorm | ||
|
C084584
Created by
admin on Fri Dec 15 15:14:06 GMT 2023 , Edited by admin on Fri Dec 15 15:14:06 GMT 2023
|
PRIMARY | |||
|
100000082753
Created by
admin on Fri Dec 15 15:14:06 GMT 2023 , Edited by admin on Fri Dec 15 15:14:06 GMT 2023
|
PRIMARY | |||
|
SUB09727MIG
Created by
admin on Fri Dec 15 15:14:06 GMT 2023 , Edited by admin on Fri Dec 15 15:14:06 GMT 2023
|
PRIMARY | |||
|
4747
Created by
admin on Fri Dec 15 15:14:06 GMT 2023 , Edited by admin on Fri Dec 15 15:14:06 GMT 2023
|
PRIMARY | |||
|
CHEMBL251940
Created by
admin on Fri Dec 15 15:14:06 GMT 2023 , Edited by admin on Fri Dec 15 15:14:06 GMT 2023
|
PRIMARY | |||
|
m8549
Created by
admin on Fri Dec 15 15:14:06 GMT 2023 , Edited by admin on Fri Dec 15 15:14:06 GMT 2023
|
PRIMARY | Merck Index | ||
|
C81580
Created by
admin on Fri Dec 15 15:14:06 GMT 2023 , Edited by admin on Fri Dec 15 15:14:06 GMT 2023
|
PRIMARY | |||
|
1398
Created by
admin on Fri Dec 15 15:14:06 GMT 2023 , Edited by admin on Fri Dec 15 15:14:06 GMT 2023
|
PRIMARY | |||
|
2107
Created by
admin on Fri Dec 15 15:14:06 GMT 2023 , Edited by admin on Fri Dec 15 15:14:06 GMT 2023
|
PRIMARY | |||
|
DB01608
Created by
admin on Fri Dec 15 15:14:06 GMT 2023 , Edited by admin on Fri Dec 15 15:14:06 GMT 2023
|
PRIMARY | |||
|
PERICYAZINE
Created by
admin on Fri Dec 15 15:14:06 GMT 2023 , Edited by admin on Fri Dec 15 15:14:06 GMT 2023
|
PRIMARY | |||
|
3405M6FD73
Created by
admin on Fri Dec 15 15:14:06 GMT 2023 , Edited by admin on Fri Dec 15 15:14:06 GMT 2023
|
PRIMARY | |||
|
758641
Created by
admin on Fri Dec 15 15:14:06 GMT 2023 , Edited by admin on Fri Dec 15 15:14:06 GMT 2023
|
PRIMARY | |||
|
31981
Created by
admin on Fri Dec 15 15:14:06 GMT 2023 , Edited by admin on Fri Dec 15 15:14:06 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)